A 48-year-old woman undergoes surgery for a stage IB clear-cell carcinoma of the ovary. Final histology shows invasion beyond the ovarian capsule but confined to the pelvis. After recovery from surgery, what is the recommended first-line adjuvant chemotherapy?

Explanation

## Adjuvant Chemotherapy for Early-Stage Clear-Cell Ovarian Carcinoma **Key Point:** Paclitaxel and carboplatin is the standard adjuvant chemotherapy for early-stage (stage IB–IC) clear-cell carcinoma of the ovary, despite the known relative chemoresistance of this histotype. ### Clinical Context: Clear-Cell Carcinoma **High-Yield:** Clear-cell carcinoma is an uncommon epithelial ovarian tumor (5–10% of EOC) with: - Association with endometriosis - Higher propensity for early-stage presentation - Relative resistance to platinum-based chemotherapy (compared to serous tumors) - Worse prognosis stage-for-stage ### Why Paclitaxel-Carboplatin Despite Chemoresistance? **Clinical Pearl:** Although clear-cell carcinomas show inherent platinum resistance (due to upregulation of drug efflux pumps and altered apoptotic pathways), paclitaxel-carboplatin remains the standard because: 1. **Evidence base:** JGOG3016 trial showed benefit of adjuvant paclitaxel-carboplatin in early-stage clear-cell and mucinous EOC 2. **No superior alternative:** No other regimen has demonstrated better outcomes in this population 3. **Synergistic mechanism:** The taxane component may overcome some platinum resistance through independent cytotoxic pathways ### Adjuvant Treatment Algorithm for Stage IB–IC EOC ```mermaid flowchart TD A[Stage IB-IC Epithelial Ovarian Cancer]:::outcome --> B{Histotype?}:::decision B -->|Serous/Endometrioid| C[Paclitaxel + Carboplatin<br/>3-6 cycles]:::action B -->|Clear-cell/Mucinous| D[Paclitaxel + Carboplatin<br/>3-6 cycles]:::action C --> E[Adjuvant completed]:::outcome D --> E ``` ### Dosing & Duration - **Paclitaxel:** 175 mg/m² IV every 21 days - **Carboplatin:** AUC 5–6 IV every 21 days - **Cycles:** 3–6 (typically 6 for stage IC) **Warning:** Do NOT confuse clear-cell ovarian carcinoma with germ-cell tumors (which use BEP regimen). Clear-cell is an epithelial tumor and requires platinum-taxane, not BEP. | Tumor Type | Histology | First-Line Adjuvant | |------------|-----------|---------------------| | Clear-cell carcinoma (EOC) | Epithelial | Paclitaxel + carboplatin | | Immature teratoma (GCT) | Germ cell | BEP (bleomycin, etoposide, cisplatin) | | Dysgerminoma (GCT) | Germ cell | BEP or EP | **Mnemonic:** **TAC for all EOC** = **T**axane + **A**lkylating agent (carboplatin) + **C**hemotherapy is the backbone for epithelial ovarian cancers of any histotype.